SG11202106251UA - Bifunctional anti-pd-1/sirpa molecule - Google Patents
Bifunctional anti-pd-1/sirpa moleculeInfo
- Publication number
- SG11202106251UA SG11202106251UA SG11202106251UA SG11202106251UA SG11202106251UA SG 11202106251U A SG11202106251U A SG 11202106251UA SG 11202106251U A SG11202106251U A SG 11202106251UA SG 11202106251U A SG11202106251U A SG 11202106251UA SG 11202106251U A SG11202106251U A SG 11202106251UA
- Authority
- SG
- Singapore
- Prior art keywords
- sirpa
- molecule
- bifunctional anti
- bifunctional
- sirpa molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18306810 | 2018-12-21 | ||
PCT/EP2019/085785 WO2020127373A1 (en) | 2018-12-21 | 2019-12-17 | Bifunctional anti-pd-1/sirpa molecule |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106251UA true SG11202106251UA (en) | 2021-07-29 |
Family
ID=65628505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106251UA SG11202106251UA (en) | 2018-12-21 | 2019-12-17 | Bifunctional anti-pd-1/sirpa molecule |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220056135A1 (en) |
EP (1) | EP3898676A1 (en) |
JP (1) | JP2022514698A (en) |
KR (1) | KR20210107062A (en) |
CN (1) | CN113574067A (en) |
AU (1) | AU2019409805A1 (en) |
BR (1) | BR112021012040A2 (en) |
CA (1) | CA3122914A1 (en) |
CL (1) | CL2021001627A1 (en) |
EA (1) | EA202191763A1 (en) |
IL (1) | IL283992A (en) |
MX (1) | MX2021007274A (en) |
SG (1) | SG11202106251UA (en) |
WO (1) | WO2020127373A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3044684A1 (en) | 2016-12-09 | 2018-06-14 | Alector Llc | Anti-sirp-alpha antibodies and methods of use thereof |
DK3883966T3 (en) | 2018-12-21 | 2023-10-16 | Ose Immunotherapeutics | HUMANIZED ANTI-HUMAN PD-1 ANTIBODY |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
CN114805592A (en) * | 2022-05-13 | 2022-07-29 | 南京吉盛澳玛生物医药有限公司 | Design, preparation and application of trispecific antibody |
WO2024028386A1 (en) * | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
CN115386550A (en) * | 2022-10-26 | 2022-11-25 | 成都诺医德医学检验实验室有限公司 | Method for evaluating anticancer effectiveness of immune cells |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
ES2206447T3 (en) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | HUMANIZED ANTIBODY FOR HEREGULINE. |
ES2162823T5 (en) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | IMMUNOGLOBULINS DESPROVISTAS OF LIGHT CHAINS. |
US5275285A (en) | 1992-12-30 | 1994-01-04 | Clegg Industries | Business card holder with sound generating microchip |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
ATE531812T1 (en) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | HUMANIZATION OF RODENT ANTIBODIES |
ES2269366T3 (en) | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | IMPROVEMENT OF AVERAGE LIFE IN CIRCULATION OF FUSION PROTEINS BASED ON ANTIBODIES. |
BR0207854A (en) | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Expression technology for proteins containing a hybrid isotype antibody moiety |
MXPA06011199A (en) | 2004-03-31 | 2007-04-16 | Genentech Inc | Humanized anti-tgf-beta antibodies. |
LT2439273T (en) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
JP6460796B2 (en) | 2012-01-17 | 2019-01-30 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | High affinity SIRP-alpha reagent |
CN105683217B (en) | 2013-05-31 | 2019-12-10 | 索伦托治疗有限公司 | Antigen binding proteins that bind to PD-1 |
CA2943681A1 (en) | 2014-04-18 | 2015-10-22 | The Research Foundation For The State University Of New York | Humanized anti-tf-antigen antibodies |
CN106535914B (en) | 2014-08-08 | 2021-08-27 | Alx 肿瘤生物技术公司 | SIRP-alpha variant constructs and uses thereof |
WO2016024021A1 (en) | 2014-08-15 | 2016-02-18 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
KR20180034588A (en) | 2015-07-30 | 2018-04-04 | 마크로제닉스, 인크. | PD-1-binding molecules and methods for their use |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
EA201890630A1 (en) | 2015-09-01 | 2018-10-31 | Эйдженус Инк. | ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION |
SG11201806120WA (en) | 2016-01-20 | 2018-08-30 | Scripps Research Inst | Ror1 antibody compositions and related methods |
AU2017210224B2 (en) * | 2016-01-21 | 2024-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with combinations of immunoregulatory agents |
WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
CN111491361B (en) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | Method for determining transmitting power, user equipment and base station |
CN107459578B (en) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | Difunctional fusion protein targeting CD47 and PD-L1 |
HUE051700T2 (en) | 2016-09-14 | 2021-03-29 | Abbvie Biotherapeutics Inc | Anti-pd-1 antibodies |
AU2018209940A1 (en) | 2017-01-18 | 2019-07-11 | Visterra, Inc. | Antibody molecule-drug conjugates and uses thereof |
CN108623689B (en) * | 2017-03-15 | 2020-10-16 | 宜明昂科生物医药技术(上海)有限公司 | Novel recombinant bifunctional fusion protein, preparation method and application thereof |
CN110958888A (en) * | 2017-03-28 | 2020-04-03 | 延龄草治疗公司 | CD47 blocking therapy |
AU2018252546A1 (en) | 2017-04-13 | 2019-10-10 | Sairopa B.V. | Anti-SIRPα antibodies |
CN111372590A (en) | 2017-09-23 | 2020-07-03 | 纪念斯隆-凯特林癌症中心 | A33 antibody compositions and methods of using the same in radioimmunotherapy |
CA3096764A1 (en) | 2018-03-05 | 2019-09-12 | Etablissement Francais Du Sang | Recombinant single chain immunoglobulins |
-
2019
- 2019-12-17 US US17/414,971 patent/US20220056135A1/en active Pending
- 2019-12-17 MX MX2021007274A patent/MX2021007274A/en unknown
- 2019-12-17 AU AU2019409805A patent/AU2019409805A1/en active Pending
- 2019-12-17 EP EP19818166.1A patent/EP3898676A1/en active Pending
- 2019-12-17 BR BR112021012040A patent/BR112021012040A2/en unknown
- 2019-12-17 WO PCT/EP2019/085785 patent/WO2020127373A1/en unknown
- 2019-12-17 EA EA202191763A patent/EA202191763A1/en unknown
- 2019-12-17 CN CN201980092872.6A patent/CN113574067A/en active Pending
- 2019-12-17 JP JP2021536199A patent/JP2022514698A/en active Pending
- 2019-12-17 SG SG11202106251UA patent/SG11202106251UA/en unknown
- 2019-12-17 KR KR1020217022853A patent/KR20210107062A/en unknown
- 2019-12-17 CA CA3122914A patent/CA3122914A1/en active Pending
-
2021
- 2021-06-14 IL IL283992A patent/IL283992A/en unknown
- 2021-06-17 CL CL2021001627A patent/CL2021001627A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3122914A1 (en) | 2020-06-25 |
CL2021001627A1 (en) | 2022-01-07 |
AU2019409805A1 (en) | 2021-07-22 |
CN113574067A (en) | 2021-10-29 |
BR112021012040A2 (en) | 2021-11-03 |
IL283992A (en) | 2021-07-29 |
WO2020127373A1 (en) | 2020-06-25 |
US20220056135A1 (en) | 2022-02-24 |
JP2022514698A (en) | 2022-02-14 |
EP3898676A1 (en) | 2021-10-27 |
EA202191763A1 (en) | 2022-03-10 |
MX2021007274A (en) | 2021-07-15 |
KR20210107062A (en) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283992A (en) | Bifunctional anti-pd-1/sirpa molecule | |
IL284052A (en) | Bifunctional molecule directed against human pd-1 | |
IL284002A (en) | Bifunctional anti-pd-1/il-7 molecule | |
FR3049459B1 (en) | BIPHASE CLEANING COMPOSITION | |
IL271790A (en) | Chromatography | |
IL272006A (en) | Bifunctional compounds | |
GB201803983D0 (en) | Materials | |
GB201708113D0 (en) | Materials | |
IL281526A (en) | Rail-switching unit | |
IL281949A (en) | Small molecule menin inhibitors | |
EP3756002C0 (en) | Liquid chromatography technique | |
GB2561947B (en) | Tissue-adhesive materials | |
EP3594305A4 (en) | Oil-repellent composition | |
IL269402A (en) | Liquid biopsy for cfrna | |
EP3563970A4 (en) | Rotary clamp | |
IL276999A (en) | Breastshield unit | |
GB201801652D0 (en) | Materials | |
GB201708013D0 (en) | Materials | |
GB201700390D0 (en) | Compounds for enhancing autophagy | |
IL282230A (en) | Chimeric molecules | |
SG11202106183TA (en) | Waterborne basecoat composition | |
EP3819231C0 (en) | Application container | |
GB2571544B (en) | Sectioning macrotome | |
EP3718435A4 (en) | Slide unit | |
ZA201801777B (en) | Clamp assembly |